SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Hyperliquid Strategies Inc issued a press release on August 27, 2026 announcing its financial results for the fiscal year ended June 30, 2026, disclosing total assets of $2,060.0 million, net income of $305.5 million, and operational metrics including $1,904.1 million in HYPE tokens.
View raw filing on EDGAR →MBX Biosciences announced the first patient dosed in its pivotal Phase 3 oPTimize trial for canvuparatide, a material clinical development milestone representing significant progress toward potential FDA registration of the company's lead product candidate.
View raw filing on EDGAR →Vince Holding Corp. completed the acquisition of October's Very Own (OVO) operating business on August 24, 2026, including 12 retail stores, e-commerce platform, wholesale relationships, and a 5% stake in OVO's IP. The transaction is structured as an asset and equity purchase and is expected to be accretive to earnings in fiscal 2027, representing a strategic expansion of VNCE's multi-brand platform.
View raw filing on EDGAR →Marc Whitten was appointed as President, Chief Executive Officer, and Board member of Dolby Laboratories effective August 27, 2026, following a formal succession process. The appointment includes detailed employment agreement terms with significant compensation and equity arrangements.
View raw filing on EDGAR →This disclosure describes a one-for-five reverse stock split and reduction in authorized shares, both approved by stockholders on August 19, 2026 and effectuated via Certificate of Amendment filed August 27, 2026. While a reverse stock split is a governance/capital structure matter (Item 5.03), it is material to investors as it affects share count, trading price, and equity compensation arrangements. The event is clearly governance-related but does not fit the specific named governance categories (exec_departure, exec_appointment, exec_compensation, shareholder_vote_results), making governance_other the appropriate classification.
View raw filing on EDGAR →Fidelity Private Credit Co LLC entered into a Second Amendment to its Senior Secured Revolving Credit Agreement, increasing aggregate Commitments from $430 million to $600 million, extending the Maturity Date to August 25, 2031, and increasing the accordion provision to $900 million, materially expanding the company's financing capacity.
View raw filing on EDGAR →Urban Outfitters issued an earnings release on August 26, 2026, disclosing Q2 and six-month financial results including record net sales of $1.66 billion and $3.14 billion respectively, net income of $240.7 million and $356.4 million, and EPS of $2.78 and $4.06. The Item 8.01 disclosure explicitly states the release "disclosed material non-public information regarding the Company's earnings for the three and six months ended July 31, 2026," and the attached exhibit is a comprehensive earnings press release with detailed financial metrics, segment performance, and management commentary.
View raw filing on EDGAR →The Board approved a new $150 million share repurchase authorization that supersedes the prior program. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses "share-repurchase programs." The authorization is material as it signals management's capital allocation priorities and confidence in the stock valuation, affecting investor assessment of the company's financial strategy.
View raw filing on EDGAR →Natuzzi received written notice from NYSE on August 26, 2026, that the exchange has suspended trading and commenced delisting proceedings for the company's ADSs due to failure to maintain the required minimum average global market capitalization of $15 million over a consecutive 30 trading-day period. This is a direct notice of delisting risk and involuntary suspension, which materially affects the registrant's continued listing status and shareholder access to U.S. capital markets.
View raw filing on EDGAR →Fidelity Private Credit Fund disclosed its July 2026 financial and operational results, including NAV per share of $24.69, total assets of $2.5 billion, a 9.85% total return since inception, and a 6.68% one-year return. The disclosure includes portfolio composition and a 9.28% distribution rate.
View raw filing on EDGAR →This exhibit is a tap issue addendum for Navios Maritime Partners L.P. documenting the issuance of USD 30,000,000 in additional senior unsecured bonds under an existing bond framework dated 5 November 2025. The addendum specifies the tap issue date (4 June 2026), the ISIN, and that net proceeds will be applied to general corporate purposes. This constitutes creation of a new direct financial obligation under the debt_issuance category.
View raw filing on EDGAR →Scholastic Corporation executed a share repurchase agreement to purchase 289,624 common shares (approximately 1.6% of outstanding shares) from the Estate of M. Richard Robinson, Jr. for $11.5 million at $39.7603 per share. While share repurchases are capital allocation decisions, they are classified under dividend_distribution in the taxonomy as a "return of capital to holders" and represent a material use of corporate cash ($11.5M from a $300M authorization). The transaction is material to investors as it reflects capital deployment strategy and impacts per-share metrics.
View raw filing on EDGAR →Antares Private Credit Fund declared a regular distribution of $0.1881 per share to shareholders of record as of August 27, 2026, payable on or about September 29, 2026.
View raw filing on EDGAR →The fund disclosed its NAV per share of $24.61 as of July 31, 2026, aggregate NAV of $812.2 million, debt levels, leverage ratios, and the status of an ongoing $2.0 billion public offering with $829.2 million in shares issued to date.
View raw filing on EDGAR →The Trust issued 296,200 shares in private placement transactions to accredited investors under Rule 506(c) of Regulation D, exempt from Securities Act registration. The filing explicitly discloses unregistered equity sales totaling $1,306,098 in aggregate value, representing a material capital raise. This is a classic dilutive issuance disclosure under Item 3.02, with the Trust's outstanding share count increasing to 2,693,500 shares as of the filing date.
View raw filing on EDGAR →Rein Therapeutics received a formal notice of delisting from Nasdaq on August 21, 2026, for failing to maintain the minimum bid price of $1.00 per share under Rule 5550(a)(1). The company has 180 days (until February 17, 2027) to regain compliance or face suspension and delisting procedures. This is a direct and material delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →This is a press release announcing Bilibili's unaudited financial results for the second quarter ended June 30, 2026. The exhibit discloses quarterly revenue (RMB7.94 billion, up 8% YoY), net profit (RMB339.1 million, up 55% YoY), gross profit margin expansion to 37.2%, and key operational metrics (DAUs of 116.5 million, up 7% YoY). The document includes detailed financial statements, segment breakdowns, and management commentary, all hallmarks of a quarterly earnings release. Material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →The Trust is disclosing a material change in its NAV calculation methodology effective September 1, 2026, transitioning from the CoinDesk Ethereum Classic Price Index to the CoinDesk Ethereum Classic Benchmark Extended Rate. This operational change affects how the Trust values its ETC holdings and calculates NAV per share, which directly impacts investor valuations. While the disclosure is primarily operational/procedural in nature, the detailed explanation of the new index methodology, constituent platform selection criteria, and calculation algorithm indicates this is a significant operational event material to shareholders.
View raw filing on EDGAR →The Company declared a regular distribution of $0.1736 per share and a special distribution of $0.0105 per share to common shareholders, payable on September 29, 2026.
View raw filing on EDGAR →The Company is conducting a continuous private placement of Common Shares under Section 4(a)(2) and Regulation D, with approximately $3.4 million in subscriptions received on August 1, 2026, and plans to continue monthly sales at NAV.
View raw filing on EDGAR →LifeVantage issued a press release on August 27, 2026 announcing financial results for the fourth quarter and full fiscal year ended June 30, 2026. The disclosure includes detailed quarterly and annual revenue, net income, EPS, and EBITDA figures, along with segment performance and balance sheet data. This is a standard earnings release disclosing quarterly and annual financial results, which is the core purpose of Item 2.02 disclosures.
View raw filing on EDGAR →The Trust is disclosing a material change in its valuation methodology effective September 1, 2026, transitioning from the CoinDesk Horizen Reference Rate to the CoinDesk Horizen Benchmark Extended Rate for calculating NAV and NAV per Share. This operational change affects how the Trust values its ZEN holdings and directly impacts shareholder valuations, making it material to investors. The detailed description of the new Index's methodology, constituent platform selection criteria, and calculation algorithm reflects a significant operational and valuation framework change rather than a routine administrative matter.
View raw filing on EDGAR →The filing discloses the completion of Diodes' acquisition of ElevATE Semiconductor for $250 million in an all-cash transaction. The Item 8.01 section explicitly states "On August 27, 2026, Diodes Incorporated (the "Company") completed its previously announced acquisition of ElevATE Semiconductor Inc." This is a material acquisition that expands the company's product portfolio and market position, with ElevATE expected to contribute approximately $50 million in revenue in the first twelve months and be immediately accretive to earnings per share.
View raw filing on EDGAR →Stifel issued a press release on August 27, 2026, disclosing selected operating results for July 31, 2026, including key performance metrics such as total client assets ($578.4 billion), fee-based client assets ($239.8 billion), bank loans, deposits, and year-over-year comparisons. Although labeled as "selected operating data" rather than full quarterly earnings, this is a periodic disclosure of financial and operational results to investors, consistent with earnings_release classification. The filing explicitly references Item 2.02 (Results of Operations and Related Results), the standard Item for earnings disclosures.
View raw filing on EDGAR →The disclosure centers on the Compensation Committee's approval of compensatory adjustments to Clay M. Gaspar's (CEO and President) compensation package, including a base salary increase to $1,500,000 retroactive to May 7, 2026, and a restricted stock award valued at $2,700,000 under the 2022 Long-Term Incentive Plan. This is a classic executive compensation arrangement disclosure under Item 5.02(e), material to investors assessing executive pay and incentive alignment.
View raw filing on EDGAR →The Company declared a regular distribution of $0.1906 per share to common shareholders, payable in cash or reinvested through a distribution reinvestment plan.
View raw filing on EDGAR →The Company disclosed a continuous private placement of Common Shares under Section 4(a)(2) and Regulation D, with approximately $8.5 million in subscriptions received on August 1, 2026, and an intention to continue selling shares monthly at NAV.
View raw filing on EDGAR →This exhibit is a quarterly earnings release for Q2 2026 (April–June 2026) disclosing MEDIROM's financial and operational performance across its salon business, HealthTech business (Lav®), and enterprise health management systems (REMONY®). The document presents key performance indicators, revenue metrics, customer data, and business highlights typical of a quarterly results announcement furnished to investors.
View raw filing on EDGAR →Charles Ryan, the Company's President, is departing effective September 8, 2026. Although the disclosure mentions severance benefits under his Executive Change in Control and Severance Agreement, the principal disclosed action is the departure itself—a named executive officer leaving the organization. The severance arrangement is incidental to the departure event.
View raw filing on EDGAR →Santander Holdings USA consummated a private placement of 500,000 shares of Series J Preferred Stock to its parent company Banco Santander, S.A., raising $500 million in capital. The transaction relied on the Section 4(a)(2) private placement exemption and was completed on August 27, 2026.
View raw filing on EDGAR →APS BDC entered into a First Amendment to its JPM Credit Facility that increased the borrowing capacity from $1.0 billion to $1.5 billion, increased the interest rate, and increased upfront fees to lenders. This material amendment expands the company's direct financial obligations and credit capacity.
View raw filing on EDGAR →Lockheed Martin entered into a new $2.25 billion 364-Day Revolving Credit Agreement on August 24, 2026, and extended its existing $3.0 billion 5-Year Revolving Credit Agreement by one year. These are material credit facilities that create new or extended direct financial obligations. While no borrowings were made at closing, the establishment of these credit arrangements represents the creation of material debt capacity and constitutes a material financial event requiring 8-K disclosure under Item 1.01.
View raw filing on EDGAR →The Board authorized a share repurchase plan for up to $10.0 million (approximately 2% of common stock), which constitutes a return of capital to shareholders. Share repurchases are classified as dividend_distribution events under the taxonomy as they represent a capital distribution mechanism. The authorization is material as it signals management's capital allocation strategy and confidence in valuation, affecting investor assessment of the company's financial position and shareholder value creation.
View raw filing on EDGAR →The Company announced a delay in releasing its six- and three-month financial results for the period ended June 30, 2026, citing "ongoing impact of recently announced developments." While the filing references "previously reported" developments without detailing them, the delay itself and the forward-looking statement that the Company expects "significant operating and net losses" signal material operational or financial stress. The announcement does not fit neatly into a specific event category (not a restatement, going-concern disclosure, or covenant breach per se), but the delay in financial reporting combined with acknowledgment of material adverse developments constitutes a material operational disclosure warranting investor attention.
View raw filing on EDGAR →This press release announces POMDOCTOR's formal initiation of U.S. market entry preparations, including recruitment of U.S.-based leadership, market assessment completion, regulatory framework structuring, product localization, and exploratory partnership discussions. While the announcement describes a strategic expansion initiative rather than a discrete completed transaction, the formal commencement of U.S. market preparation—a major geographic expansion for a digital healthcare company—represents a material operational and strategic milestone that would affect a reasonable investor's assessment of the company's growth trajectory and future revenue potential. The disclosure does not fit the specific event categories (M&A, exec changes, financial results, etc.) but clearly constitutes a material operational/strategic business event.
View raw filing on EDGAR →ABVC BioPharma completed a partial legal and structural separation of its subsidiary BioKey Cayman on August 21, 2026, distributing approximately 15% of BioKey Cayman's ordinary shares to ABVC shareholders as a pro rata dividend while retaining 85% control. The transaction involved multiple definitive agreements (Separation Agreement, Transitional Services Agreement, Tax Matters Agreement, and Employee Matters Agreement) and transformed BioKey Cayman from a wholly owned subsidiary into an independent reporting company with ABVC as controlling shareholder.
View raw filing on EDGAR →This 8-K discloses a spin-off transaction whereby ABVC BioPharma distributes approximately 15% of BioKey (Cayman), Inc. to ABVC shareholders, with BioKey becoming an independent, Exchange Act reporting entity. The Separation and Distribution Agreement dated June 22, 2026, and related transaction documents (Transitional Services Agreement, Tax Matters Agreement, Employee Matters Agreement) are attached as exhibits. This constitutes a material change of control and structural separation meeting the definition of ma_activity under Items 1.01/2.01.
View raw filing on EDGAR →This disclosure announces a major strategic infrastructure expansion in Pohang, Korea, including a nearly six-fold increase in electrical capacity (130 MW to 750 MW), acquisition of 1.3 million square feet of land, facility expansion from 24,000 to 482,000 square feet, and a $20.7 million Korean government grant. While this involves operational and strategic business developments (power infrastructure, land acquisition, facility expansion, production scaling), it does not fit the specific categories of M&A activity (no acquisition of another company), debt issuance, or other named financial events. The event is clearly operational and material to investors assessing the company's growth trajectory and manufacturing capacity, but is best classified as an operational/strategic milestone rather than a specific named event type.
View raw filing on EDGAR →The filing discloses that Onfolio Holdings received notice from Nasdaq on July 2, 2026, that its common stock failed to maintain the minimum bid price of $1.00 required by Listing Rule 5550(a)(2). Although the company subsequently regained compliance by August 25, 2026, the core event is the delisting risk notice and the company's efforts to cure the deficiency. Item 3.01 explicitly addresses "Notice of Delisting or Failure to Satisfy a Continued Listing Rule," and the filing documents the company's prior non-compliance and subsequent remediation through a reverse split.
View raw filing on EDGAR →The filing discloses successful completion of three large-animal procedures using NeuroOne's StereoCED™ platform, demonstrating technical feasibility and a novel combination of drug delivery and electrophysiological recording. The company expects to recognize related revenue in fiscal Q4 2026 and plans to launch the platform for human investigational clinical studies later in the quarter. This represents a material operational and product development milestone for a medical device company, though it does not fit neatly into the specific operational categories (it is not a contract, partnership, or restructuring). The revenue recognition expectation and clinical launch timeline make this material to investors assessing the company's progress toward commercialization.
View raw filing on EDGAR →Faraday Future announced a multi-phase execution roadmap for its "Built in USA" robotics acceleration program, including targets to bring its robot factory online by year-end 2026 and launch first new EAI Device products in February 2027. The disclosure also covers distributor recruitment, planned $5 billion U.S. investment over ten years, and new product launches (Next Futurist and Next Aegis robots). This is a strategic operational and business development announcement that would materially affect investor assessment of the company's product roadmap, manufacturing capabilities, and market positioning, though it does not fit neatly into other specific event categories.
View raw filing on EDGAR →The 6-K discloses the appointment of Ms. Simin Tan as Chief Financial Officer on August 27, 2026, effective immediately. Although the report also mentions the resignation of the prior CFO (Ms. Zhixin Li), the principal disclosed action is the appointment of a new officer to a named executive position. The report includes biographical information, employment and indemnification agreements, and confirms no conflicts of interest, all consistent with an exec_appointment disclosure under Item 5.02.
View raw filing on EDGAR →Katherine Williams was appointed as Chief Financial Officer of the US Subsidiary and as an executive director of the Registrant on August 21, 2026, with detailed employment and directorship agreements specifying compensation ($465,000 base salary plus $40,000 signing bonus, EUR 200,000 directorship compensation), performance bonuses, severance, and equity vesting terms. The principal disclosed action is the appointment of a named executive to a material officer role, making this an exec_appointment event.
View raw filing on EDGAR →Charlton Aria Acquisition Corp issued an unsecured Working Capital Note in the principal amount of up to $500,000 to its sponsor on August 25, 2026, with terms including default interest accrual and conversion rights into equity. The note was issued under Section 4(a)(2) exemption as an unregistered sale of convertible securities, creating a direct financial obligation and potential dilution to existing shareholders upon conversion.
View raw filing on EDGAR →The 6-K discloses results of a Special Meeting of Shareholders held on August 26, 2026, at which shareholders approved authorization for the Board to effect reverse share splits at ratios ranging from 1-for-4 to 1-for-40. This is a shareholder vote result on a material corporate action (reverse split authorization) that would affect investor holdings and capital structure.
View raw filing on EDGAR →This joint press release announces the completion of a business combination between Pasqal Holding SA and Bleichroeder Acquisition Corp. II (a SPAC), with Pasqal as the surviving entity. The transaction establishes Pasqal as a public company with approximately $360 million in cash at closing and Nasdaq listing under ticker "PSQL" effective August 28, 2026. This is a material change-of-control event that fundamentally transforms Pasqal from a private company to a publicly traded entity.
View raw filing on EDGAR →Bleichroeder Acquisition Corp. II completed its business combination with Pasqal Holding SA on August 27, 2026, with Pasqal as the surviving company now trading on Nasdaq under ticker 'PSQL' with approximately $360 million in cash at closing. The transaction was approved by shareholders on August 25, 2026, and represents a material change of control and merger that transforms Pasqal from a private company to a publicly traded entity.
View raw filing on EDGAR →Bleichroeder Acquisition Corp. II notified Nasdaq of the consummation of its business combination and requested suspension of trading in its units, Class A ordinary shares, and redeemable warrants, with planned filing of Form 25 for delisting and Form 15 for deregistration under the Exchange Act. This is an orderly delisting of Bleichroeder's securities in connection with the SPAC merger completion, with Pasqal's new Nasdaq listing replacing it.
View raw filing on EDGAR →Banco de Chile announced the placement of senior, dematerialized bearer bonds (Serie FT Bonds) in the local Chilean market on August 27, 2026, for a total amount of CLF 1,100,000 with maturity October 1, 2032, at an average rate of 2.92%. This is a creation of a new direct financial obligation and is explicitly filed as "Material Information" with the Chilean Financial Market Commission, meeting the definition of debt_issuance.
View raw filing on EDGAR →This is a press release dated August 27, 2026, announcing Newegg's second quarter 2026 financial results for the three months ended June 30, 2026. The exhibit contains consolidated financial statements (balance sheet, income statement, cash flows), operational metrics, and management commentary on quarterly performance. The disclosure of quarterly earnings is a material event affecting investor assessment of the registrant's financial condition and operating performance.
View raw filing on EDGAR →